Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.42 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21400182 | 0.80 | PRCP (0.45) | CYP11B2IDO1PDPK1PLAU | |
| SCHEMBL27014167 | 0.72 | ACHE (0.41) | IDO1 | |
| SCHEMBL11235903 | 0.71 | IDO1 (0.52) | CYP11B2IDO1PDPK1PLAUCA1 | |
| SCHEMBL9776879 | 0.71 | IDO1 (0.52) | CYP11B2IDO1PDPK1PLAUCA1 | |
| SCHEMBL11450268 | 0.71 | IDO1 (0.52) | CYP11B2IDO1PDPK1PLAUCA1 | |
| SCHEMBL11450267 | 0.71 | IDO1 (0.52) | CYP11B2IDO1PDPK1PLAUCA1 | |
| SCHEMBL4023125 | 0.71 | IDO1 (0.52) | CYP11B2IDO1PDPK1PLAUCA1 | |
| SCHEMBL11235907 | 0.71 | IDO1 (0.52) | CYP11B2IDO1PDPK1PLAUCA1 | |
| SCHEMBL25079056 | 0.70 | IDO1 (0.37) | IDO1PDPK1PLAUCA1CA2 | |
| Hydrochloric Acid SCHEMBL7334124 | 0.70 | IDO1 (0.53) | CYP11B2IDO1PDPK1PLAUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018146-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018146-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ, INC. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018146-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | PINK1, NME4, AK2 | CYP11B2 842/4885IDO1 2783/4885CYP19A1 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.